| Gastrointestinal dysfunction in Parkinson's disease A Fasano, NP Visanji, LWC Liu, AE Lang, RF Pfeiffer The Lancet Neurology 14 (6), 625-639, 2015 | 825 | 2015 |
| The prion hypothesis in Parkinson's disease: Braak to the future NP Visanji, PL Brooks, LN Hazrati, AE Lang Acta neuropathologica communications 1, 1-12, 2013 | 349 | 2013 |
| The role of neuronal nicotinic acetylcholine receptors in acute and chronic neurodegeneration MJ O'neill, TK Murray, V Lakics, NP Visanji, S Duty Current Drug Targets-CNS & Neurological Disorders 1 (4), 399-411, 2002 | 277 | 2002 |
| α-Synuclein strains target distinct brain regions and cell types A Lau, RWL So, HHC Lau, JC Sang, A Ruiz-Riquelme, SC Fleck, E Stuart, ... Nature neuroscience 23 (1), 21-31, 2020 | 238 | 2020 |
| Increased 5‐HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations P Huot, TH Johnston, T Darr, LN Hazrati, NP Visanji, D Pires, JM Brotchie, ... Movement disorders 25 (10), 1399-1408, 2010 | 171 | 2010 |
| α-Synuclein-based animal models of Parkinson's disease: challenges and opportunities in a new era NP Visanji, JM Brotchie, LV Kalia, JB Koprich, A Tandon, JC Watts, ... Trends in neurosciences 39 (11), 750-762, 2016 | 168 | 2016 |
| AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a … CW Ip, LC Klaus, AA Karikari, NP Visanji, JM Brotchie, AE Lang, ... Acta neuropathologica communications 5, 1-12, 2017 | 149 | 2017 |
| Colonic mucosal α-synuclein lacks specificity as a biomarker for Parkinson disease NP Visanji, C Marras, DS Kern, A Al Dakheel, A Gao, LWC Liu, AE Lang, ... Neurology 84 (6), 609-616, 2015 | 149 | 2015 |
| Dietary resveratrol administration increases MnSOD expression and activity in mouse brain EL Robb, L Winkelmolen, N Visanji, J Brotchie, JA Stuart Biochemical and biophysical research communications 372 (1), 254-259, 2008 | 145 | 2008 |
| α-Synuclein Membrane Association Is Regulated by the Rab3a Recycling Machinery and Presynaptic Activity*♦ RHC Chen, S Wislet-Gendebien, F Samuel, NP Visanji, G Zhang, ... Journal of Biological Chemistry 288 (11), 7438-7449, 2013 | 142 | 2013 |
| Alimentary, my dear Watson? The challenges of enteric α‐synuclein as a Parkinson's disease biomarker NP Visanji, C Marras, LN Hazrati, LWC Liu, AE Lang Movement Disorders 29 (4), 444-450, 2014 | 110 | 2014 |
| Targeted delivery of an Mecp2 transgene to forebrain neurons improves the behavior of female Mecp2-deficient mice DGM Jugloff, K Vandamme, R Logan, NP Visanji, JM Brotchie, ... Human molecular genetics 17 (10), 1386-1396, 2008 | 108 | 2008 |
| Regulation of myeloid cell phagocytosis by LRRK2 via WAVE2 complex stabilization is altered in Parkinson’s disease KS Kim, PC Marcogliese, J Yang, SM Callaghan, V Resende, ... Proceedings of the National Academy of Sciences 115 (22), E5164-E5173, 2018 | 104 | 2018 |
| Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease NP Visanji, SH Fox, T Johnston, G Reyes, MJ Millan, JM Brotchie Neurobiology of disease 35 (2), 184-192, 2009 | 104 | 2009 |
| PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons … NP Visanji, A Orsi, TH Johnston, PA Howson, K Dixon, N Callizot, ... The FASEB Journal 22 (7), 2488-2497, 2008 | 101 | 2008 |
| Pharmacological characterization of psychosis‐like behavior in the MPTP‐lesioned nonhuman primate model of Parkinson's disease NP Visanji, J Gomez‐Ramirez, TH Johnston, D Pires, V Voon, JM Brotchie, ... Movement disorders: official journal of the Movement Disorder Society 21 (11 …, 2006 | 97 | 2006 |
| Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities NP Visanji, AE Lang, GG Kovacs Translational neurodegeneration 8, 1-13, 2019 | 85 | 2019 |
| Effect of Ser-129 phosphorylation on interaction of α-synuclein with synaptic and cellular membranes NP Visanji, S Wislet-Gendebien, LW Oschipok, G Zhang, I Aubert, ... Journal of Biological Chemistry 286 (41), 35863-35873, 2011 | 82 | 2011 |
| Histamine H3 receptor agonists reduce L‐dopa–induced chorea, but not dystonia, in the MPTP‐lesioned nonhuman primate model of Parkinson's disease J Gomez‐Ramirez, TH Johnston, NP Visanji, SH Fox, JM Brotchie Movement disorders 21 (6), 839-846, 2006 | 69 | 2006 |
| Nonsteroidal Anti‐inflammatory Use and LRRK2 Parkinson's Disease Penetrance M San Luciano, CM Tanner, C Meng, C Marras, SM Goldman, AE Lang, ... Movement Disorders 35 (10), 1755-1764, 2020 | 68 | 2020 |
